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Asthma in elderly is characterized 
by increased sputum neutrophils, lower airway 
caliber variability and air trapping
F. Schleich* , S. Graff, F. Guissard, M. Henket, V. Paulus and R. Louis
Abstract 
Background: Elderly asthmatics represent an important group that is often excluded from clinical studies. In this 
study we wanted to present characteristics of asthmatics older than 70 years old as compared to younger patients.
Methods: We conducted a retrospective analysis on a series of 758 asthmatics subdivided in three groups: lower 
than 40, between 40 and 70 and older than 70. All the patients who had a successful sputum induction were included 
in the study.
Results: Older patients had a higher Body Mass Index, had less active smokers and were more often treated with 
Long Acting anti-Muscarinic Agents. We found a significant increase in sputum neutrophil counts with ageing. There 
was no significant difference in blood inflammatory cell counts whatever the age group. Forced expiratory volume in 
one second  (FEV1) and  FEV1/FVC values were significantly lower in elderly who had lower bronchial hyperresponsive-
ness and signs of air trapping. We found a lower occurrence of the allergic component in advanced ages. Asthmatics 
older than 70 years old had later onset of the disease and a significant longer disease duration.
Conclusion: Our study highlights that asthmatics older than 70 years old have higher bronchial neutrophilic inflam-
mation, a poorer lung function, signs of air trapping and lower airway variability. The role of immunosenescence 
inducing chronic low-grade inflammation in this asthma subtype remains to be elucidated.
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Background
Bronchial asthma is a chronic inflammatory disease of 
the airways. Because of improved life expectancy, the 
proportion of individuals aged upper than 70  years old 
is growing worldwide. Elderly asthmatics represent an 
important group that is often excluded from clinical 
studies. However asthma in the elderly exacerbates as 
often as in non-elderly asthma and different predictors of 
exacerbations were recently identified with fixed airway 
obstruction and chronic rhinosinusitis being predictors 
in the elderly population while eosinophils was a strong 
predictor in non-elderly asthmatics [1].
Asthma in older adults is either diagnosed after the 
age of 70 or have a history of long-standing disease. The 
prevalence of asthma in the most advanced ages is similar 
to that of younger ages [2]. Asthma in the elderly is often 
underdiagnosed or diagnosed as COPD thus leading to 
improper treatment.
In elderly, comorbidities are more frequently encoun-
tered [3] and polypharmacy increases the risk of low 
adherence and interactions between drugs. Moreover, 
immunosenescence has been associated with chronic 
low-grade inflammation called inflammaging with 
incompletely elucidated underlying mechanisms [4, 5].
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There are few data on asthma features in elderly peo-
ple. Asthma is however not uncommon in subjects aged 
70 years old or more with prevalence between 3 and 6% 
[2]. In this study, we wanted to compare clinical and 
functional features and bronchial inflammation in young, 
middle-aged and elderly asthmatics and discuss the 
potential treatment implications of these observations.
Material and methods
Subject characteristics
We conducted a retrospective study on a series of 758 
patients with asthma recruited from the University 
Asthma Clinic of Liege between October 2010 and Janu-
ary 2019 after subdividing the population studied in three 
groups of age: lower than 40, between 40 and 70 and 
older than 70. The patients came from routine practice 
to University Hospital and were recruited by two clini-
cians involved in asthma. Entry criteria were any patients 
with asthma aged 18 years old or more who accepted to 
undergo detailed investigation at the Asthma Clinic. The 
visits were not parts of an asthma trial. All the patients 
that had a successful sputum induction were included in 
the study.
Asthma was diagnosed based on the presence of 
chronic respiratory symptoms such as cough, breath-
lessness or dyspnoea together with the demonstration of 
airflow variability. The latter was defined by airway hyper-
responsiveness shown by one or more of the follow-
ing: increase in Forced Expiratory Volume in 1 s  (FEV1) 
of > 12% and 200  ml following inhalation of 400  µg sal-
butamol or inhaled concentration of methacholine pro-
voking a 20% fall in  FEV1 of < 16  mg/ml. Methacholine 
challenge was performed according to a standardised 
methodology as previously described [6]. Subjects were 
characterised as atopic if they had at least one positive 
specific IgE (> 0.35kU/l; Phadia) for at least one common 
aeroallergen (cat, dog, house dust mites, grass pollen, 
tree pollen and a mixture of moulds).
Study design
Patients underwent FeNO measurement at a flow rate 
of 50 ml/s according to the ERS/ATS recommendations 
(NIOX, Aerocrine, Sweden). FeNO was first measured 
and followed by spirometry with bronchodilation, spu-
tum induction and blood sampling. All tests were per-
formed on the same day.
Quality of life was assessed using the self-administered 
Asthma Quality of Life Questionnaire (AQLQ) [7] and 
asthma control by the Juniper Asthma Control Question-
naire (ACQ) [8].
Sputum was induced and processed as previously 
reported [9] and was successful in 78% of the patients 
encountered in our asthma clinic which is similar to 
previous report [10]. Cell count were estimated on sam-
ples centrifuged (Cytospin) and stained with Diff Quick 
after counting 500 cells (Dade, Brussels, Belgium).
This study was conducted with the approval of the eth-
ics committee of CHU Liege.
Statistical analyses
The results were expressed as mean ± SD or mean ± SEM 
for continuous variables; median and interquartile 
ranges (IQR) were preferred for skewed distributions. 
For categorical variables, the number of observations 
and percentages were given in each category. Compari-
sons between different subgroups were performed with 
a Kruskal–Wallis test. The Spearman correlation coeffi-
cient was used to measure the association between clini-
cal parameters.
The results were considered to be significant at the 5% 
critical level (p < 0.05).
Results
Demographic characteristics
Older asthmatics were more frequently overweight 
with a BMI of 27 as compared to 23 kg/m2 for asthmat-
ics younger than 40  years old (p < 0.001). They also had 
lower rates of active smokers (8% versus 20%, p < 0.001) 
(Table  1). We did not find an increased risk of uncon-
trolled asthma or exacerbations in our asthmatic patients 
aged > 70. The lowest asthma quality of life was observed 
in the middle-aged asthmatics due to higher emotional 
trigger (score of 4.4 points as compared to 5.2 for asth-
matics younger than 40 and to 5.4 for asthmatics older 
than 70  years old, p = 0.019). Asthmatics older than 
70  years old had later onset of the disease (55  years 
old versus 15 for patients younger than 40 and 35 for 
patients aged between 40 and 70  years old, p < 0.0001) 
and a longer disease duration (15  years versus 13  years 
for patients aged between 40 and 70, p = 0.0013). Focus-
ing on treatment characteristics, we did not find differ-
ences in terms of Inhaled Corticosteroids (ICS) treatment 
and ICS dose, treatment with Long Acting B2 Agonists 
(LABA) or anti-leukotrienes in the elderly asthmatics 
as compared to younger patients. However the propor-
tion of patients treated with Long acting antimuscarinic 
agents (LAMA) was higher in older patients (8% as com-
pared to 0.6% for patients younger than 40, p = 0.001).
Functional and inflammatory characteristics
Looking at inflammatory biomarkers, we did not find 
any significant difference in exhaled nitric oxide levels 
according to the age subgroup (Table 2). We found a sig-
nificant increase in sputum neutrophil counts with age-
ing (37% for patients younger than 40, 48% for patients 
aged between 40 and 70 and 57% for patients older than 
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70  years old, p < 0.0001). Sputum eosinophils taken in 
absolute value were higher in the middle-aged group 
(35% versus 12% for patients younger than 40, p < 0.05). 
Sputum macrophages were higher in younger patients. 
There was no significant difference in blood inflamma-
tory cell counts whatever the age group.
FEV1 values were significantly lower in asthmatics 
older than 70  years old (84% versus 96% for < 40  years 
and 90% for 40–70 years old, p < 0.05). A same trend was 
observed for  FEV1/FVC values that were significantly 
lower in asthmatics older than 70 years old (76% versus 
82% for asthmatics younger than 40, p < 0.001) (Fig.  1, 
Table  2) while reversibility after bronchodilatation was 
not different as compared to younger groups. The dose of 
methacholine required to induce a bronchoconstriction 
was higher in the elderly asthmatics (8.8  mg/ml versus 
2  mg/ml for < 40  years old, p = 0.021). Airway conduct-
ance were however significantly lower in asthmatics older 
than 70  years old (0.7 versus 0.8  kPa/sec for < 70  years 
old, p < 0.01). We also found signs of air trapping in older 
asthmatics with RV/TLC of 53% as compared to 29% for 
asthmatics < 40 years old and to 44% for asthmatics aged 
between 40 and 70  years old (p < 0.0001) (Fig.  2). Diffu-
sion was found to be significantly lower but KCO was 
well preserved in elderly asthma.
We found lower levels of IgE (83 kU/l versus 330 kU/l 
for asthmatics < 40  years old and 112  kU/l for asthmat-
ics aged between 40 and 70  years old, p = 0.001) and a 
lower rate of sensitization to common aeroallergens in 
advanced ages (Table 3). Looking at asthma inflammatory 
phenotypes, we found a higher proportion of neutro-
philic asthma (22%, defined as sputum neutrophils > 76%) 
and mixed granulocytic asthma (10%, defined as spu-
tum neutrophils > 76% and sputum eosinophils > 3%), 
while there was a lower proportion of paucigranulocytic 
(33%) and eosinophilic asthma (35%) in older asthmatics 
(Table 4).
Link between air trapping and/or sputum neutrophils 
and functional and inflammatory characteristics
We found a significant correlation between sputum 
neutrophilic inflammation and air trapping (r = 0.25, 
p < 0.0001), reflected by RV/TLC ratio and asthma dura-
tion (r = 0.08, p = 0.049) while there was a negative asso-
ciation with  FEV1/FVC (r = − 0.07, p = 0.048),  FEV1 
(r = − 0.15, p < 0.0001) and sGaw (r = − 0.08, p = 0.02) 
(Table 5).
Looking at increased residual volume on total lung 
capacity ratio, we found a significant negative correlation 
with  FEV1/FVC (r = − 0.46, p < 0.0001),  FEV1 (r = − 0.47, 
Table 1 Demographic characteristics of patients according to the age group
BMI body mass index, ACQ asthma control questionnaire, AQLQ: asthma quality of life questionnaire, ICS inhaled corticosteroids, dose in beclomethasone equivalent, 
LABA long acting B2 agonists, LAMA long acting antimuscarinic agents, IL5 interleukin 5
Comparison between < 40 and 40–70 (*), comparison between < 40 and ≥ 70 (#), comparison between 40 and 70 and ≥ 70 (^). P < 0.05 (1 sign); p < 0.01 (2 signs), 
p < 0.001 (3 signs)
 < 40 years 40–70  ≥ 70 Global p-value
n 186 468 104
Gender (M/F) 73/113 (39%) 180/289 (38%) 47/57 (45%)  > 0.05
Weight, kg 69 (58–79) 74 (63–86)*** 71 (62–86)### 0.0002
Height, cm 168 (161–176) 167 (162–175) 164 (158–170)#^ 0.000004
BMI, kg/m2 22.8 (15–41) 26.4 (16–42)*** 27 (18–37)###^^^ 0.000001
Smokers 20% 23% 8%###^^^
Pack-yr 0 (0–25) 0 (0–45)*** 0 (0–50) ## 0.000001
ACQ 1.7 (1–2.57) 1.9 (1–3) 1,9 (1–3,86)  > 0.05
AQLQ 4.9 (3.9–5.97) 4.5 (3.5–5.6)* 5 (3.8–5.9)#^ 0.001
Emotional trigger 5.2 (1–7) 4.4 (1–7)** 5.4 (2–7)^^ 0.019
Environmental stimulus 4.8 (1–7) 4.5 (1–7) 4.8 (1.3–7)  > 0.05
Symptoms 4.8 (1.2–7) 4.3 (1.2–7) 5 (1.8–7) 0.006
Age of onset 15 (5–25) 35 (15–50)*** 55 (32–68)###^^^ 0.000001
Duration of asthma 11 (1–19) 13 (2–35)*** 15 (3–40)### 0.0013
ICS 400 (0–1000) 500 (0–1000) 500 (0–1000)  > 0.05
LABA, % 58 63 64  > 0.05
LAMA, % 0,6 5** 8## 0.001
Anti-leukotrienes (%) 25 25 33  > 0.05
Anti-IL5 (n) 0 5 1  > 0.05
Exacerbations (n) 0 (0–7) 0 (0–10) 0 (0–6)  > 0.05
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p < 0.0001) (Fig. 3) and sGaw (r = − 0.41, p < 0.0001) while 
there was a positive relationship with asthma duration 
(r = 0.16, p = 0.0001) (Table 6).
Discussion
We found that our elderly population of asthmatics was 
characterized by poorer lung function, limited response 
to methacholine challenge and signs of air trapping. We 
showed that older asthmatics exhibit increased sputum 
neutrophils without any change in blood neutrophils and 
lower levels of total and specific IgE.
Woodruff et  al. previously showed that older age cor-
related with increased sputum neutrophil percentage but 
not eosinophil percentage [11]. Although it is well known 
that neutrophils are increased in elderly [12], it seems 
that neutrophil chemotactic activity [13] and extracel-
lular DNA traps production [14] declines with age. Our 
study confirms an increase in sputum neutrophils with 
ageing with a consequent increase in neutrophilic and 
Table 2 Functional and inflammatory characteristics of patients according to the age group
FeNO fraction of exhaled nitric oxide, AV absolute value, FEV1 forced expiratory volume in one second, FVC forced vital capacity, TLC: total lung capacity, FRC functional 
residual capacity, RV residual volume, DLCO diffusion of CO, KCO transfer coefficient, sGaw airway compliance, PC20 concentration of methacholine provoking a 20% 
fall in  FEV1, IgE immunoglobulin E, RAST specific IgE, HDM house dust mites, CRP C reactive protein
Comparison between < 40 and 40–70 (*), comparison between < 40 and ≥ 70 (#), comparison between 40 and 70 and ≥ 70 (^). P < 0.05 (1 sign); p < 0.01 (2 signs), 
p < 0.001 (3 signs)
 < 40 years 40–70  ≥ 70 Global p-value
n 186 468 104
FeNO, ppb 35(15–70) 27 (14–52) 22 (16–49)  > 0.05
Sputum eosinophils, % 1.4 (0.2–9.5) 2.5 (0.2–14.4) 2.7 (0.2–11.4)  > 0.05
Sputum eosinophils, AV 11.7 (0.32–96) 34.6 (4–175)* 25.3 (0.79–239) 0.0083
Sputum neutrophils, % 37 (15.7–65.4) 48.4 (25–68)*** 57 (29–81)###^^^  < 0.000001
Sputum neutrophils, AV 538 (213–1554) 721 (283–2292) 1160 (323–3527)##^^ 0.000004
Sputum macrophages, % 34 (14–53) 21 (11–36)*** 15 (7–25)###^^^  < 0.000001
Sputum lymphocytes, % 1 (0.2–2) 1 (0..2–2) 1 (0.2–1.8)  > 0.05
Sputum weight 2 (1.35–3.4) 2.32 (1.35–3.9) 2.32 (1.24–3,6)  > 0.05
Blood eosinophils, % 3.2 (1.7–5.8) 2.7 (1.5–4.6) 2.9 (1.9–4.8)  > 0.05
Blood eosinophils, /mm3 240 (145–465) 220 (120–390) 270 (143–385)  > 0.05
Blood neutrophils, % 55 (49–63) 57 (49–63) 60 (53–64)  > 0.05
Blood neutrophils, /mm3 4180 (3315–5157) 4217 (3570–5550) 4220 (3520–5440)  > 0.05
FEV1, % 96 (86–100) 90 (76–104)* 84 (69–97)
###^ 0.000004
Reversibility, % 7.7 (3–15) 8 (2.7–15) 11 (3.4–18)  > 0.05
FVC,% 97 ( 89–108) 97 (82–111) 90 (78–101)  > 0.05
FEV1/FVC, post,% 82 (77–86) 77 (70–83)** 76 (69–82)
##  < 0.000001
TLC, % 96 (89–104) 100 (91–112) 102 (96–114)  > 0.05
FRC, % 101 104 106  > 0.05
RV/TLC, % 29 (24–35) 44 (36–51)*** 53 (45–60)####^^^^  < 0.000001
DLCO, % 78 76 69#^ 0.0003
KCO, % 93 90 95  > 0.05
sGaw, kPa/sec 0.84 (0.65–1.1) 0.8 (0.6–1.1) 0.7 (0.5–1)##^^ 0.019
PC20M mg/ml 2 (0.5–7.2) 3,7 (1.17–15)* 8,8 (1.7–16)# 0.021
IgE, kU/l 330 (107–624) 112 (46–324)**** 83 (29–380)####^^^^ 0.001
RAST HDM 2.3 (0.3–25.4) 0.3 (0.1–1)*** 0.3 (0.1–0.3)####  < 0.000001
RAST birch 0.3 (0–4.4) 0.3 (0.1–0.3)* 0.3 (0.1–0.3)### 0.00004
RAST cat 0.7 (0.1–14) 0.3 (0–0.5)* 0.3 (0–0.3)###  < 0.000001
RAST dog 0.3 (0.1–2.7) 0.3 (0–0.3)* 0.3 (0–0.3)###  < 0.000001
RAST grass pollen 2.8 (0.3–25) 0.3 (0.1–0.5)*** 0.3 (0.1–0.3)###  < 0.000001
RAST moulds 0.29 (0.1–0.3) 0.1 (0–0.3) 0.3 (0–0.3) 0.00012
CRP, mg/l 1.5 (0.6–3.5) 1.75 (0.8–4) 2.3 (1.1–4.5)  > 0.05
Fibrinogen, g/l 2,9 (2.5–3.2) 3,1 (2.8–3.8)** 3,5 (3.2–4.3)##^^  < 0.000001
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mixed granulocytic phenotypes. This increase in sputum 
neutrophils might not be due to smoking history as there 
were less smokers in patients older than 70 years old. We 
found that bronchial neutrophilic inflammation was cor-
related with air trapping, airway obstruction and asthma 
duration. We previously found from a multiple logistic 
regression that age and FRC were independently associ-
ated with sputum neutrophilia in a general population 
of asthmatics [15]. This suggests that airway neutrophils 
may contribute to reduction of inspiratory capacity seen 
in some asthmatics. Accordingly, two pediatric studies 
reported that percentage neutrophils in bronchoalveo-
lar lavage directly correlated with air trapping (FRC) in 
children with cystic fibrosis [16, 17]. Neutrophils can 
be retained in the pulmonary microvasculature due to 
their low deformability, resulting in a higher concentra-
tion than in the systemic circulation. It is thought that 
this high concentration of cells facilitates their effective 
recruitment to sites of inflammation. It might be that age-
ing induce tissue remodeling with an increase in micro-
vasculature permeability and air trapping due to a loss of 
elastic recoil and reduced radial traction in distal airways. 
The role of immunosenescence inducing chronic neutro-
philic inflammation in this asthma subtype remains to be 
elucidated.
Older age was previously associated with worse lung 
function [11, 18] and lower bronchial hyperresponsive-
ness to methacholine. Chuang et al. [19] previously found 
Fig. 1 FEV1% predicted value in asthmatics classified according to 
age. Patients younger than 40 years old (group 1), aged between 
40 and 70 (group 2) or older than 70 years old (group 3). Group 1 
different from group 2 (p < 0.05) and from group 3 (p < 0.001). Group 
2 different from group 3 (p < 0.05)
Fig. 2 Residual volume on total lung capacity ratio according to age 
group. Patients younger than 40 years old (group 1), aged between 
40 and 70 (group 2) or older than 70 years old (group 3). Group 1 
different from group 2 (p < 0.00001) and from group 3 (p < 0.00001). 
Group 2 different from group 3 (p < 0.00001)
Table 3 Proportions of  positive skin prick test and/
or  specific IgE in  patients younger or  older than  70  years 
old
 < 70 years (%)  ≥ 70 years (%) p-value
House dust mites 47 21 < 0.0001
Cat 37 9 < 0.0001
Dog 25 8 < 0.0001
Moulds 25 10 0.0007
Grass pollens 39 9 < 0.0001
Birch 20 1 0.029
Table 4 Frequence of  inflammatory phenotypes 
between different age subgroups
Comparison between < 40 and 40–70 (*), comparison between < 40 and > 70 (#), 
comparison between 40–70 and > 70 (^). P < 0.05 (1 sign); p < 0.01 (2 signs), 
p < 0.001 (3 signs)
< 40 40–70  ≥ 70
Paucigranulocytic N = 91 (49%) 156 (33%)** 34 (33%)#
Eosinophilic 70 (38%) 220 (47%)* 37 (35%)^
Neutrophilic 20 (10%) 85 (18%)* 23 (22%)##
Mixed granulocytic 5 (3%) 7 (2%) 10 (10%)#^^^
Table 5 Correlations between  sputum neutrophil counts 




95% CI for rho p-value
RV/TLC 0.25 0.17 to 0.30 < 0.0001
FEV1/FVC − 0.07 − 0.13 to − 0.003 0.048
FEV1, % pred − 0.15 − 0.22 to − 0.09 < 0.0001
sGaw − 0.08 − 0.15 to − 0.01 0.02
Asthma duration 0.08 0.00007 to 0.15 0.049
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poorer baseline lung function in the elderly asthmatics 
while there was no significant difference in percentage 
of  FEV1 reversibility between the young and the elderly 
patients. Our older patients with asthma had a longer 
disease duration and this could increase the risk of airway 
remodeling. With regards to this lower lung function, we 
found a higher proportion of asthmatics treated with 
long acting anti-muscarinic agents in the older group. 
Further studies should be performed in elderly asthmat-
ics to evaluate the effect of long acting bronchodilators 
on airway obstruction in this specific population of asth-
matics, often excluded from clinical trials.
We found lower levels of IgE in asthmatics older than 
70 years old as compared to younger asthmatics. Moreo-
ver, among the six aero-allergens tested, house dust mite 
was the most common in our population of elderly asth-
matics, with one fifth of sensitized patients as compared 
to half of the younger population. This is line with the 
results of King et al. [20]. The decrease of prevalence of 
atopy that we observed in elderly may be explained by a 
gradual decline in immune function called immunose-
nescence and changes in tissue structure. The immu-
noinflammatory responses change during the ageing 
process as a consequence of continuous damage caused 
by chronic antigenic stress and repeated environmental 
aggressions throughout life. As an example it has been 
found that T cells expressing high levels of CD25 con-
stitutively inhibit the activation of allergen-responsive T 
cells [21] and increase with age, particularly after 60 years 
old [22]. As allergen sensitive T-Cells are responsible for 
B cells activation and the production of IgE, this might 
explain the observed decreased proportions of patients 
sensitized to common aero-allergens and the decreased 
levels of IgE in asthmatics older than 70 years old. More-
over, the elderly have elevated NK cells, most of which 
are  CD8+ and produce  TH1 cytokines with an inhibitory 
effect on type-2 allergic inflammation [23] and that may 
induce neutrophilic inflammation. This anti-type-2 or 
pro-type-1 process is more pronounced in older asthmat-
ics than in healthy elderly.
It was previously suggested that elderly patients were at 
risk for developing uncontrolled asthma [24]. In elderly, 
unintentional non adherence with inhalation therapy 
may lead to significant impairment in asthma control. 
Complexity of the treatment, cognitive, hearing and vis-
ual impairments, low coordination, tremor and arthritis 
may affect their ability to follow treatment prescribed. 
Our data show similar results for the asthma control 
questionnaires in the different age subgroups. Our data 
are in keeping with the paper of Ponte et al. [18] were age 
did not predict poor control of asthma if proper treat-
ment was offered.
In a healthy population, FeNO levels evolution 
throughout ageing were found to reach a plateau between 
14 and 45 years in female and between 16 and 59 years 
in males, then FeNO levels start to increase linearly until 
80 [25]. We did not find the same trend in our asthmatic 
population as FeNO levels were found to be lower in the 
older subgroup.
In conclusion, our study highlights that asthmat-
ics older than 70  years old have higher bronchial neu-
trophilic inflammation, a poorer lung function, signs 
of air trapping and lower airway caliber variability. 
Fig. 3 Correlations between  FEV1 (a) and  FEV1/FVC (b) and RV/TLC





95% CI for rho p-value
FEV1/FVC − 0.46 − 0.51 to − 0.41 < 0.0001
FEV1, % pred − 0.47 − 0.53 to − 0.42 < 0.0001
sGaw − 0.41 − 0.47 to − 0.35 < 0.0001
Asthma duration 0.16 0.08 to 0.23 0.0001
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Immunosenescence and airway remodeling, partly due to 
longer disease duration certainly play a role in higher air-
way obstruction, loss of caliber variability and in promot-
ing type-1 inflammation.
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